×
About 7,518 results

ALLMedicine™ Gastrointestinal Stromal Tumors Center

Research & Reviews  3,573 results

Avapritinib in Patients With Advanced Gastrointestinal Stromal Tumors Following at Leas...
https://doi.org/10.1002/onco.13674
The Oncologist; George S, Jones RL et. al.

Jan 16th, 2021 - Most gastrointestinal stromal tumors (GIST) driven by KIT or platelet-derived growth factor receptor A (PDGFRA) mutations develop resistance to available tyrosine kinase inhibitor (TKI) treatments. NAVIGATOR is a two-part, single arm, dose escalat...

A Case of Duodenal Neuroendocrine Tumor Accompanied by Gastrointestinal Stromal Tumors ...
https://doi.org/10.12659/AJCR.927562
The American Journal of Case Reports; Makita N, Kayahara M et. al.

Jan 11th, 2021 - BACKGROUND Type 1 neurofibromatosis (NF1) is known to be associated with not only neurogenic tumors but also gastrointestinal (GI) neoplasms. However, there are few reports on vascular lesions and the incidence is unknown. CASE REPORT We report he...

Clinicopathological characteristics and outcomes of gastrointestinal stromal tumors wit...
https://doi.org/10.1371/journal.pone.0245153
PloS One; Do IG, Jung KU et. al.

Jan 7th, 2021 - Progranulin (PGRN) is known to promote tumorigenesis and proliferation of several types of cancer cells. However, little is known about the clinicopathological features of patients with gastrointestinal stromal tumors (GISTs) with regard to PGRN e...

Translating Knowledge About the Immune Microenvironment of Gastrointestinal Stromal Tum...
https://doi.org/10.1007/s11864-020-00806-z 10.1093/annonc/mdm410 10.1146/annurev.pathmechdis.3.121806.151538 10.1007/s11845-016-1410-1 10.1016/j.canep.2015.10.031 10.1126/science.279.5350.577 10.1016/S0002-9440(10)65250-9 10.1182/blood.V96.3.925 10.1056/NEJM200104053441404 10.1038/sj.onc.1204704 10.1097/00000658-200001000-00008 10.1200/JCO.2007.13.4452 10.1056/NEJMoa020461 10.1016/S0140-6736(01)06535-7 10.1016/S0140-6736(04)17098-0 10.1200/JCO.2008.17.4284 10.1186/s12885-020-6597-x 10.1016/S0140-6736(12)61857-1 10.1016/S0140-6736(06)69446-4 10.2217/fon-2016-0192 10.1158/1078-0432.CCR-16-2349 10.1016/B978-0-12-800267-4.00003-1 10.1002/(SICI)1097-0142(20000201)88:3<577::AID-CNCR13>3.0.CO;2-V 10.1016/j.neo.2016.11.010 10.1158/0008-5472.CAN-13-3723 10.1093/neuonc/not149 10.1158/1078-0432.CCR-16-3122 10.2217/fon-2017-0245 10.1038/cgt.2016.58 10.1158/1078-0432.CCR-16-1163 10.1158/0008-5472.CAN-13-0371 10.1002/bjs.10127 10.18632/oncotarget.10038 10.1111/his.13382 10.1080/2162402X.2019.1617588 10.1111/cei.12392 10.1097/CCO.0000000000000201 10.1038/nm.2366 10.1080/2162402X.2014.1002729 10.1126/science.aar3593 10.1172/JCI91190 10.1172/JCI21102 10.1007/s00262-011-1185-1 10.1038/nm.2438 10.1001/jamaoncol.2017.1617 10.1200/JCO.2018.36.4_suppl.55
Current Treatment Options in Oncology References and Reco... Chantharasamee J, Adashek JJ et. al.

Jan 5th, 2021 - The role of targeted therapy is firmly established for gastrointestinal stromal tumors (GISTs); other modalities for targeting this disease are necessary for recurrent and refractory disease. There are several lines of evidence pointing to an acti...

Single-cell transcriptome analysis revealed the heterogeneity and microenvironment of g...
https://doi.org/10.1111/cas.14795
Cancer Science; Mao X, Yang X et. al.

Jan 4th, 2021 - Gastrointestinal stromal tumor (GIST) is the most common mesenchymal tumor of the human gastrointestinal tract. In this study, we performed single-cell RNA sequencing (RNA-seq) on intra- and peri-tumor tissues from GIST patients with the aim of di...

see more →

Guidelines  11 results

Longer-term imatinib treatment extends OS among patients with GIST
https://www.healio.com/hematology-oncology/sarcoma/news/online/{e2646bcc-d52d-4050-898d-1d3154b179b4}/longer-term-imatinib-treatment-extends-os-among-patients-with-gist

May 30th, 2020 - An extended course of imatinib increased OS among patients with gastrointestinal stromal tumors, or GIST, according to long-term study results presented during the ASCO20 Virtual Scientific Program.

Three Years of Imatinib Improves OS in High-Risk Operable GIST
https://dailynews.ascopubs.org/do/10.1200/ADN.20.200183/full/

May 28th, 2020 - Approximately half of deaths can be avoided with the use of 3 years of adjuvant imatinib in the first decade after surgery for high-risk gastrointestinal stromal tumors (GIST), according to long-term data from the Scandinavian Sarcoma Group XVIII/...

Chinese consensus on management of tyrosine kinase inhibitor-associated side effects in...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6295840
World Journal of Gastroenterology; Li J, Wang M et. al.

Dec 25th, 2018 - Tyrosine kinase inhibitors (TKIs) have improved the overall survival of patients with gastrointestinal stromal tumors (GISTs), but their side effects can impact dose intensity and, consequently, the clinical benefit. To date, no guideline or conse...

Gastrointestinal stromal tumours: ESMO–EURACAN Clinical Practice Guidelines for diagnosis, t...
https://academic.oup.com/annonc/advance-article/doi/10.1093/annonc/mdy095/5004450
Casali, P. G.

May 27th, 2018 - Gastrointestinal stromal tumours (GISTs) are rare tumours, with an estimated unadjusted incidence of around 1/100 000/year. This only covers clinically relevant GISTs, since, if investigated, a much higher number of lesions ≤ 1 cm in diameter (mic.

Guidelines for time-to-event end point definitions in sarcomas and gastrointestinal str...
https://doi.org/10.1093/annonc/mdu360
Annals of Oncology : Official Journal of the European Soc... Bellera CA, Penel N et. al.

Jul 29th, 2014 - The use of potential surrogate end points for overall survival, such as disease-free survival (DFS) or time-to-treatment failure (TTF) is increasingly common in randomized controlled trials (RCTs) in cancer. However, the definition of time-to-even...

see more →

Drugs  2 results see all →

Clinicaltrials.gov  3,767 results

Avapritinib in Patients With Advanced Gastrointestinal Stromal Tumors Following at Leas...
https://doi.org/10.1002/onco.13674
The Oncologist; George S, Jones RL et. al.

Jan 16th, 2021 - Most gastrointestinal stromal tumors (GIST) driven by KIT or platelet-derived growth factor receptor A (PDGFRA) mutations develop resistance to available tyrosine kinase inhibitor (TKI) treatments. NAVIGATOR is a two-part, single arm, dose escalat...

A Case of Duodenal Neuroendocrine Tumor Accompanied by Gastrointestinal Stromal Tumors ...
https://doi.org/10.12659/AJCR.927562
The American Journal of Case Reports; Makita N, Kayahara M et. al.

Jan 11th, 2021 - BACKGROUND Type 1 neurofibromatosis (NF1) is known to be associated with not only neurogenic tumors but also gastrointestinal (GI) neoplasms. However, there are few reports on vascular lesions and the incidence is unknown. CASE REPORT We report he...

Clinicopathological characteristics and outcomes of gastrointestinal stromal tumors wit...
https://doi.org/10.1371/journal.pone.0245153
PloS One; Do IG, Jung KU et. al.

Jan 7th, 2021 - Progranulin (PGRN) is known to promote tumorigenesis and proliferation of several types of cancer cells. However, little is known about the clinicopathological features of patients with gastrointestinal stromal tumors (GISTs) with regard to PGRN e...

Translating Knowledge About the Immune Microenvironment of Gastrointestinal Stromal Tum...
https://doi.org/10.1007/s11864-020-00806-z 10.1093/annonc/mdm410 10.1146/annurev.pathmechdis.3.121806.151538 10.1007/s11845-016-1410-1 10.1016/j.canep.2015.10.031 10.1126/science.279.5350.577 10.1016/S0002-9440(10)65250-9 10.1182/blood.V96.3.925 10.1056/NEJM200104053441404 10.1038/sj.onc.1204704 10.1097/00000658-200001000-00008 10.1200/JCO.2007.13.4452 10.1056/NEJMoa020461 10.1016/S0140-6736(01)06535-7 10.1016/S0140-6736(04)17098-0 10.1200/JCO.2008.17.4284 10.1186/s12885-020-6597-x 10.1016/S0140-6736(12)61857-1 10.1016/S0140-6736(06)69446-4 10.2217/fon-2016-0192 10.1158/1078-0432.CCR-16-2349 10.1016/B978-0-12-800267-4.00003-1 10.1002/(SICI)1097-0142(20000201)88:3<577::AID-CNCR13>3.0.CO;2-V 10.1016/j.neo.2016.11.010 10.1158/0008-5472.CAN-13-3723 10.1093/neuonc/not149 10.1158/1078-0432.CCR-16-3122 10.2217/fon-2017-0245 10.1038/cgt.2016.58 10.1158/1078-0432.CCR-16-1163 10.1158/0008-5472.CAN-13-0371 10.1002/bjs.10127 10.18632/oncotarget.10038 10.1111/his.13382 10.1080/2162402X.2019.1617588 10.1111/cei.12392 10.1097/CCO.0000000000000201 10.1038/nm.2366 10.1080/2162402X.2014.1002729 10.1126/science.aar3593 10.1172/JCI91190 10.1172/JCI21102 10.1007/s00262-011-1185-1 10.1038/nm.2438 10.1001/jamaoncol.2017.1617 10.1200/JCO.2018.36.4_suppl.55
Current Treatment Options in Oncology References and Reco... Chantharasamee J, Adashek JJ et. al.

Jan 5th, 2021 - The role of targeted therapy is firmly established for gastrointestinal stromal tumors (GISTs); other modalities for targeting this disease are necessary for recurrent and refractory disease. There are several lines of evidence pointing to an acti...

Single-cell transcriptome analysis revealed the heterogeneity and microenvironment of g...
https://doi.org/10.1111/cas.14795
Cancer Science; Mao X, Yang X et. al.

Jan 4th, 2021 - Gastrointestinal stromal tumor (GIST) is the most common mesenchymal tumor of the human gastrointestinal tract. In this study, we performed single-cell RNA sequencing (RNA-seq) on intra- and peri-tumor tissues from GIST patients with the aim of di...

see more →

News  161 results

EMA Green Light for Avapritinib for GIST, Acalabrutinib for CLL
https://www.staging.medscape.com/viewarticle/934648

Jul 26th, 2020 - The European Medicines Agency (EMA) Committee for Medicinal Products for Human Use (CHMP) has given a thumbs up to two new oncology drugs.  The Committee has recommended granting conditional marketing authorization for avapritinib (Ayvakit, Bluepr...

EMA Green Light for Avapritinib for GIST, Acalabrutinib for CLL
https://www.medscape.com/viewarticle/934648

Jul 26th, 2020 - The European Medicines Agency (EMA) Committee for Medicinal Products for Human Use (CHMP) has given a thumbs up to two new oncology drugs.  The Committee has recommended granting conditional marketing authorization for avapritinib (Ayvakit, Bluepr...

Ripretinib Extends Survival When All Else Fails in Advanced GIST
https://www.medscape.com/viewarticle/933412

Jul 5th, 2020 - NEW YORK (Reuters Health) - Treatment with oral ripretinib significantly prolonged survival in patients with advanced gastrointestinal stromal tumors (GIST) who did not respond or were intolerant to three other tyrosine-kinase inhibitors in the IN...

Longer-term imatinib treatment extends OS among patients with GIST
https://www.healio.com/hematology-oncology/sarcoma/news/online/{e2646bcc-d52d-4050-898d-1d3154b179b4}/longer-term-imatinib-treatment-extends-os-among-patients-with-gist

May 30th, 2020 - An extended course of imatinib increased OS among patients with gastrointestinal stromal tumors, or GIST, according to long-term study results presented during the ASCO20 Virtual Scientific Program.

Three Years of Imatinib Improves OS in High-Risk Operable GIST
https://dailynews.ascopubs.org/do/10.1200/ADN.20.200183/full/

May 28th, 2020 - Approximately half of deaths can be avoided with the use of 3 years of adjuvant imatinib in the first decade after surgery for high-risk gastrointestinal stromal tumors (GIST), according to long-term data from the Scandinavian Sarcoma Group XVIII/...

see more →

Patient Education  4 results see all →